(Q35851801)

10 August 2017

1 reference

title

A call for replicating vector prime-protein boost strategies in HIV vaccine design (English)

1 reference

10 August 2017

0 references

1 reference

Marjorie Robert-Guroff

series ordinal

2

object named as

Marjorie Robert-Guroff

1 reference

10 August 2017

Nina V Malkevitch

1

1 reference

10 August 2017

1 August 2004

1 reference

Expert Review of Vaccines

10 August 2017

1 reference

10 August 2017

3

1 reference

10 August 2017

4 Suppl

1 reference

10 August 2017

S105-17

1 reference

New hope for an AIDS vaccine

10 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Antibody neutralization and escape by HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Immunopathogenesis and immunotherapy in AIDS virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

HIV-1 Tat-based vaccines: from basic science to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Safety profile of recombinant canarypox HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Alphavirus replicon particles as candidate HIV vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.4.S105

10.1586/14760584.3.4.S105

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15285710